ES2157953T3 - Dispositivo de administracion por rotura osmotica activada por el ph. - Google Patents

Dispositivo de administracion por rotura osmotica activada por el ph.

Info

Publication number
ES2157953T3
ES2157953T3 ES94301026T ES94301026T ES2157953T3 ES 2157953 T3 ES2157953 T3 ES 2157953T3 ES 94301026 T ES94301026 T ES 94301026T ES 94301026 T ES94301026 T ES 94301026T ES 2157953 T3 ES2157953 T3 ES 2157953T3
Authority
ES
Spain
Prior art keywords
beneficial agent
osmotic
osmagent
break
semipermeable membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94301026T
Other languages
English (en)
Inventor
Scott M Herbig
Kelly L Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2157953T3 publication Critical patent/ES2157953T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)

Abstract

UN DISPOSITIVO DE DESCARGAS OSMOTICAS PARA EL SUMINISTRO DE UN AGENTE BENEFICIOSO A UN ENTORNO ACUOSO. EL DISPOSITIVO CONSTA DE UN AGENTE BENEFICIOSO Y DE UN AGENTE OSMOTICO RODEADO, AL MENOS EN PARTE, POR UNA MEMBRANA SEMIPERMEABLE. ALTERNATIVAMENTE, EL AGENTE BENEFICIOSO PUEDE ACTUAR TAMBIEN A MODO DE AGENTE OSMOTICO. LA MEMBRANA SEMIPERMEABLE ES PERMEABLE AL AGUA Y SUSTANCIALMENTE IMPERMEABLE AL AGENTE BENEFICIOSO Y AL AGENTE OSMOTICO. HAY UN ELEMENTO DISPARADOR ACOPLADO A LA MEMBRANA SEMIPERMEABLE (EJ. DOS MEDIAS CAPSULAS UNIDAS). EL ELEMENTO DISPARADOR SE ACTIVA CON UN PH DE 3 A 9 Y DISPARA EL SUMINISTRO EVENTUAL, PERO REPENTINO, DEL AGENTE BENEFICIOSO. ESTOS DISPOSITIVOS LA LIBERACION DISPARADA POR MEDIO DEL PH DEL NUCLEO DEL AGENTE BENEFICIOSO A MODO DE BOLO MEDIANTE UNA DESCARGA OSMOTICA.
ES94301026T 1993-02-25 1994-02-11 Dispositivo de administracion por rotura osmotica activada por el ph. Expired - Lifetime ES2157953T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/023,227 US5358502A (en) 1993-02-25 1993-02-25 PH-triggered osmotic bursting delivery devices

Publications (1)

Publication Number Publication Date
ES2157953T3 true ES2157953T3 (es) 2001-09-01

Family

ID=21813831

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94301026T Expired - Lifetime ES2157953T3 (es) 1993-02-25 1994-02-11 Dispositivo de administracion por rotura osmotica activada por el ph.

Country Status (19)

Country Link
US (2) US5358502A (es)
EP (1) EP0612520B1 (es)
JP (1) JP2862222B2 (es)
CN (1) CN1098286A (es)
AT (1) ATE202927T1 (es)
AU (1) AU660386B2 (es)
CA (1) CA2116288C (es)
DE (1) DE69427664T2 (es)
DK (1) DK0612520T3 (es)
ES (1) ES2157953T3 (es)
FI (1) FI113941B (es)
GR (1) GR3036497T3 (es)
IL (1) IL108691A0 (es)
MX (1) MX9401396A (es)
NO (1) NO312123B1 (es)
NZ (1) NZ250967A (es)
PT (1) PT612520E (es)
TW (1) TW283641B (es)
ZA (1) ZA941262B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
US5800422A (en) * 1995-06-02 1998-09-01 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
US5902605A (en) * 1996-04-18 1999-05-11 Alza Corporation Drug delivery device with minimal residual drug retention
ES2203963T3 (es) * 1997-05-30 2004-04-16 Osmotica Corp. Dispositivo osmotico multicapa.
US6186991B1 (en) 1998-06-29 2001-02-13 The Procter & Gamble Company Disposable article having a responsive system including a mechanical actuator
US7772455B1 (en) 1997-11-14 2010-08-10 The Procter & Gamble Company Disposable article providing improved management of bodily exudates
US6149636A (en) 1998-06-29 2000-11-21 The Procter & Gamble Company Disposable article having proactive sensors
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
EP1044021B1 (en) * 1998-01-05 2009-09-23 The University of Washington Enhanced transport using membrane disruptive agents
US6660301B1 (en) * 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US6407308B1 (en) 1998-06-29 2002-06-18 The Procter & Gamble Company Disposable article having sensor to detect impending elimination of bodily waste
US6160198A (en) * 1998-06-29 2000-12-12 The Procter & Gamble Company Disposable article having a discontinuous responsive system
EP1091720B1 (en) 1998-06-29 2004-05-19 The Procter & Gamble Company Disposable absorbent article having a responsive system including an electrical actuator
US6342037B1 (en) 1998-06-29 2002-01-29 The Procter & Gamble Company Device having fecal component sensor
US6433244B1 (en) 1998-06-29 2002-08-13 The Procter & Gamble Company Disposable treatment article having a responsive system
EP1091718B1 (en) 1998-06-29 2007-09-05 The Procter & Gamble Company Disposable treatment article having a responsive system
CA2336094A1 (en) 1998-06-29 2000-01-06 The Procter & Gamble Company Disposable waste management device
US6372951B1 (en) 1998-06-29 2002-04-16 The Procter & Gamble Company Disposable article having sensor to detect impending elimination of bodily waste
US6359190B1 (en) 1998-06-29 2002-03-19 The Procter & Gamble Company Device for measuring the volume of a body cavity
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
WO2001051092A2 (en) * 2000-01-07 2001-07-19 University Of Washington Enhanced transport of agents using membrane disruptive agents
AU2001249221A1 (en) 2000-03-20 2001-10-03 Biosphere Medical, Inc. Injectable and swellable microspheres for tissue bulking
PL355844A1 (en) * 2000-08-09 2004-05-31 Panacea Biotec Limited Novel pharmaceutical compositions of anti-tubrcular drugs and process for their preparation
GB2369997B (en) * 2000-12-12 2004-08-11 Johnson & Johnson Medical Ltd Dressings for the treatment of exuding wounds
DE10100689A1 (de) * 2001-01-09 2002-07-18 Henkel Kgaa Wasch- und reinigungsaktive Substanzen enthaltende Mikrokapseln
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
AU2002352988A1 (en) * 2001-11-30 2003-06-17 Bristol-Myers Squibb Company Pipette configurations and arrays thereof for measuring cellular electrical properties
DE10209979A1 (de) * 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040143221A1 (en) * 2002-12-27 2004-07-22 Shadduck John H. Biomedical implant for sustained agent release
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
US20060177507A1 (en) * 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20050139805A1 (en) * 2003-11-06 2005-06-30 Dale Koster Dechlorinating tablet and method of manufacture
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
WO2005097210A1 (en) * 2004-03-26 2005-10-20 The University Of Utah Research Foundation Bioresponsive polymer system for delivery of microbicides
CN101395469B (zh) * 2006-02-28 2012-12-05 霍夫曼-拉罗奇有限公司 评价低溶解度化合物吸收特性的方法
WO2007109584A1 (en) * 2006-03-16 2007-09-27 University Of Washington Temperature-and ph-responsive polymer compositions
JP2010510320A (ja) * 2006-11-21 2010-04-02 マクニール−ピーピーシー・インコーポレーテツド 改変型放出鎮痛性懸濁液
US7981688B2 (en) 2007-03-08 2011-07-19 University Of Washington Stimuli-responsive magnetic nanoparticles and related methods
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
WO2009028583A1 (ja) * 2007-08-29 2009-03-05 Shionogi & Co., Ltd. コーティング製剤の製造方法
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JP2012505211A (ja) * 2008-10-10 2012-03-01 アルヴィン ファーマシューティカルズ インコーポレーティッド チモーゲンの迅速な活性化を促進する剤形
US8426214B2 (en) * 2009-06-12 2013-04-23 University Of Washington System and method for magnetically concentrating and detecting biomarkers
WO2011008534A1 (en) * 2009-06-30 2011-01-20 Boston Scientific Scimed, Inc. Implantable self-powered biodegradable medical device to treat or prevent reperfusion injury
WO2011039686A1 (en) 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
US9080933B2 (en) 2009-11-09 2015-07-14 University Of Washington Through Its Center For Commercialization Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
US20110117668A1 (en) * 2009-11-09 2011-05-19 University Of Washington Through Its Center For Commercialization Self-powered smart diagnostic devices
AU2011214865B2 (en) 2010-02-10 2015-11-05 Queen's University At Kingston Water with switchable ionic strength
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013014972B1 (pt) * 2010-12-15 2020-12-29 Queen's University At Kingston método para remover um soluto da solução aquosa ou para concentrar a solução aquosa diluida através da modulação da força iônica de uma solução aquosa
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US20160060589A1 (en) * 2014-09-01 2016-03-03 Abnova (Taiwan) Corporation Particle transporting system and method of operating the same
EP3365029A2 (en) * 2015-10-20 2018-08-29 Takasago International Corporation Fragrance delivery device, system, and method
JP6944822B2 (ja) * 2017-06-27 2021-10-06 持田製薬株式会社 易服用性カプセル
WO2021014360A1 (en) 2019-07-23 2021-01-28 Pfizer Inc. Oral modified release dosage forms
AU2020385054B2 (en) 2019-11-14 2023-10-12 Pfizer Inc. 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4135514A (en) * 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4539199A (en) * 1981-01-14 1985-09-03 Egyt Gyogyszervegyeszeti Gyar Sustained release pharmaceutical compositions
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
DE3243710A1 (de) * 1982-11-25 1984-05-30 Delma, elektro- und medizinische Apparatebau GmbH, 7200 Tuttlingen Operationsleuchte
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4773907A (en) * 1982-12-20 1988-09-27 Alza Corporation Primary delivery system comprising secondary dosage form
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
US4587117A (en) * 1983-06-06 1986-05-06 Alza Corporation Medical device for delivering drug to pH environments greater than 3.5
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4705515A (en) * 1984-10-26 1987-11-10 Alza Corporation Dosage form for administering drug of the colon
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
US4830855A (en) * 1987-11-13 1989-05-16 Landec Labs, Inc. Temperature-controlled active agent dispenser
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
EP0408496A3 (en) * 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
EP0565560B1 (en) * 1991-01-03 1994-09-28 Glaxo Canada Inc. Method for production of solid pharmaceutical preparation
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
NZ242065A (en) * 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
US5364634A (en) * 1991-11-08 1994-11-15 Southwest Research Institute Controlled-release PH sensitive capsule and adhesive system and method

Also Published As

Publication number Publication date
CN1098286A (zh) 1995-02-08
DK0612520T3 (da) 2001-09-17
CA2116288A1 (en) 1994-08-26
DE69427664T2 (de) 2001-10-25
EP0612520A2 (en) 1994-08-31
JP2862222B2 (ja) 1999-03-03
NO312123B1 (no) 2002-03-25
US5358502A (en) 1994-10-25
US5609590A (en) 1997-03-11
FI940866A0 (fi) 1994-02-24
AU660386B2 (en) 1995-06-22
ZA941262B (en) 1995-08-24
FI940866A (fi) 1994-08-26
EP0612520B1 (en) 2001-07-11
GR3036497T3 (en) 2001-11-30
PT612520E (pt) 2001-12-28
AU5640094A (en) 1994-09-22
CA2116288C (en) 1997-11-18
FI113941B (fi) 2004-07-15
MX9401396A (es) 1994-08-31
NO940642D0 (no) 1994-02-24
EP0612520A3 (en) 1995-11-15
NZ250967A (en) 1996-02-27
ATE202927T1 (de) 2001-07-15
JPH072645A (ja) 1995-01-06
NO940642L (no) 1994-08-26
DE69427664D1 (de) 2001-08-16
TW283641B (es) 1996-08-21
IL108691A0 (en) 1994-05-30

Similar Documents

Publication Publication Date Title
ES2157953T3 (es) Dispositivo de administracion por rotura osmotica activada por el ph.
ATE133561T1 (de) Orale, osmotische vorrichtung
LV12452A (lv) Aktivas vielas vaginala ievadisanas sistema
ES551505A0 (es) Un sistema osmotico lipidico para dispersar agentes farmacologicamente activos.
BR0107646A (pt) Dispositivo osmótico dentro de um dispositivo osmótico
ES2130622T3 (es) Sistema para la administracion transdermica de farmacos.
IT1201136B (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
DE69322286D1 (de) Verabreichungsvorrichtungen mit gestützten flüssigen membranen
DE69425828D1 (de) Osmotische vorrichtung mit dampfdurchlaessiger beschichtung
AR065073A2 (es) Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo
IE882898L (en) Solubility modulated drug delivery device
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
NO941351L (no) Peroralt leveringssystem for legemidler
KR880005944A (ko) 삼투성 연속 분배 경구용 전달 시스템

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 612520

Country of ref document: ES